MIDDLESEX, U.K.—GlaxoSmithKline PLC (GSK) has announced plans to invest more than $790 million in its U.K. manufacturing sites with the creation of as many as 1,000 new jobs. GSK will be investing $553 million in the construction of a biopharmaceutical manufacturing facility to be located in Ulverston, Cumbria, and construction on the new facility will begin in 2014 or 2015. GSK will invest $158 million in its two Scottish manufacturing sites, and $126 million at its sites in Ware in Hertfordshire and Barnard Castle in County Durham.

 

Andrew Witty, CEO of GSK, said the Ulverston facility will be GSK’s “first new U.K. factory for almost 40 years,” and the company is “actively considering other investments in our U.K. manufacturing network.”